$34.51 $0.77 (2.3%)

04:15 PM EDT on 07/02/20

Pfizer Inc (NYSE:PFE)

CAPS Rating: 4 out of 5

A research-based pharmaceutical company, Pfizer discovers, develops, manufactures, and markets prescription medicines such as Lipitor, Celebrex, and Viagra.

Current Price $34.51 Mkt Cap $191.7B
Open $0.00 P/E Ratio 12.12
Prev. Close $34.51 Div. (Yield) $1.48 (4.3%)
Daily Range $0.00 - $0.00 Volume 10,197,594
52-Wk Range $27.88 - $44.11 Avg. Daily Vol. 30,770,669

Caps

How do you think NYSE:PFE will perform against the market?

Add Stock to CAPS Watchlist

All Players

5,517 Outperform
579 Underperform
 

All-Star Players

983 Outperform
75 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NYSE:PFE Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

DanCooper76 (< 20)
Submitted June 28, 2013

$10 billion buyback

poerqwa (< 20)
Submitted September 27, 2014

The stock has been underperforming for a while now. AstraZeneca and other pharma-peers are showing a nice growth(in stock price). The recent fail of Pfizer to take over AstraZeneca(AZN) and nothing special in the works, only proves to me that for the… More

Recent Community Commentary

Read the most recent pitches from players about PFE.

Recs

0
Member Avatar TMFAdriaCimino (55.60) Submitted: 6/6/2020 5:05:47 PM : Outperform Start Price: $36.24 NYSE:PFE Score: -2.13

I like the growth in Pfizer's biopharma business, and the decision to merge its generic business with Mylan should streamline business overall.

Recs

0
Member Avatar robryan1 (< 20) Submitted: 6/3/2020 10:00:29 AM : Outperform Start Price: $35.89 NYSE:PFE Score: -4.19

With Consumer Healthcare gone and Upjohn on its way out, investors will see the headline margin growth YOY. PFE is a solid business trying to get back to what it knows. I think there will be some hiccups after a few patents expire in 2022 (either 2022 or 2021, I can't remember), but thats where their current large Phase 3 pipeline comes in even if Ibrance doesnt produce the $10B they expect. My biggest concern though is their debt-to-asset net Goodwill.

Recs

0
Member Avatar Atn1027 (52.71) Submitted: 5/22/2020 9:00:48 PM : Outperform Start Price: $37.84 NYSE:PFE Score: -11.23

This stock is a cash flow machine and undervalued based on current product line alone. Add the significant optionality of a possible Coronavirus vaccine and you have a great risk to reward relationship.

Leaderboard

Find the members with the highest scoring picks in PFE.

Score Leader

flickib41

flickib41 (75.67) Score: +179.69

The Score Leader is the player with the highest score across all their picks in PFE.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
compfreak999 77.26 6/20/2008 Outperform 1Y $10.81 +219.37% +144.63% +74.74 1 Comment
ProEdgeBiker 87.65 6/16/2008 Outperform NS $11.09 +211.29% +136.70% +74.59 0 Comment
AlIskandarani 63.24 6/12/2008 Outperform 1Y $10.97 +214.47% +139.88% +74.59 1 Comment
megamillion2 58.66 6/12/2008 Outperform 5Y $10.97 +214.47% +139.88% +74.59 0 Comment
erin5811 98.18 6/12/2008 Outperform 3Y $10.97 +214.47% +139.88% +74.59 0 Comment
mitcjam 82.32 6/12/2008 Outperform 5Y $10.97 +214.47% +139.88% +74.59 0 Comment
jeffkhunter 55.19 6/12/2008 Outperform 3Y $10.97 +214.47% +139.88% +74.59 0 Comment
rosco643 < 20 6/12/2008 Outperform 5Y $10.97 +214.47% +139.88% +74.59 0 Comment
SomersGOP < 20 6/23/2008 Outperform 1Y $10.85 +218.08% +143.58% +74.50 0 Comment
DrDrBob 83.57 6/23/2008 7/19/2008 Outperform 3Y $10.85 +218.08% +143.58% +74.50 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for PFE.